Bio-Rad Buys Sanofi Dx
Executive Summary
Bio-Rad Laboratories is buying Sanofi Diagnostics from Sanofi-Synthelabo in order to increase its mass, goegraphical scope, and diversity of product lines. Bio-Rad, which has life sciences and analytical instruments businesses in addition to a clinical diagnostics business, makes a number of assays and it is looking to increase its presence in infectious diseases, where Sanofi is strong. Sanofi makes tests for infectious diseases and is strong in HIV diagnostics. Burt does Bio-Rad have the wherewithall to make this deal work, given the two companies differ in culture and strengths?
You may also be interested in...
How Big Can Bio-Rad Get?
Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.
Korean Biopharma Today And Tomorrow: M&A, Investment, Governance
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.